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Since the discovery of hyperuricemia as the cause of gout in the early 1800s, hypertension, 
cardiovascular disease and kidney disease have also been related to increased serum uric 
acid (UA) levels in subsequent years (Nakagawa et al., 2006); patients with gout had a much 
higher prevalence of hypertension (25-50%), mild-to-moderate kidney disease (20-60%) 
(Kutzing & Firestein, 2008) and cardiovascular disease (90%) compared to the general 
population. However, conflicting results regarding the role of UA as the causative factor in 
diseases other than gouty arthritis resulted in a shift of interest away from UA. In recent 
years, uric acid regained the lost popularity due to new findings in a number of disease 
states including hypertension, renal disease, metabolic syndrome and many more (Feig et 
al., 2008).  
Hyperuricemia arises from excess dietary purine or ethanol intake, decreased renal 
excretion of UA, or from tumor lyses in lymphoma, leukaemia, or solid tumours (Kutzing & 
Firestein, 2008). Finally, several drugs alter UA handling by the kidney, for example drug 
therapy with candesartan (Li et al., 2008) or both loop- and thiazide diuretics, all of which 
increase the net urate reabsorption (Suliman et al., 2006). In the majority of individuals, 
hyperuricemia will be asymptomatic, but as UA tends to precipitate in tissues and in other 
body fluids, persistent hyperuricemia may eventually lead to the accumulation of urate 
crystals in many places, resulting in either acute painful conditions, like gout/tophaceous 
gout/gouty arthritis, urolithiasis, or, in severe cases, like tumor lysis syndrome, in acute UA 
nephropathy (Riegersperger et al., 2011). 
In recent years, increased fructose intake, particularly via sweetened beverages, started to 
attract more attention from the medical community. During the last two centuries, at least in 
the western world, dietary fructose intake dramatically increased, with corresponding 
increases in serum UA levels (Feig et al., 2008). The increase in fructose intake and 
hyperuricemia is now being associated to the development of metabolic syndrome. 
Hyperuricemia is associated with an increased risk for developing CKD (Obermayr et al., 
2008) and a risk factor for renal dysfunction in patients with rheumatoid arthritis 
(Daoussis et al., 2009). Retrospective data suggest an influence of hyperuricemia on graft 
loss after kidney transplantation (Haririan et al., 2010). A screening among 18,020 
individuals with chronic kidney diseases (CKD) found a 20.6% prevalence of 
hyperuricemia. A cross-sectional study in individuals aged over 40 years found 10.5% 
prevalence of CKD, and among these, 26% were hyperuricemic (Shan et al., 2010). A 
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multi-center study of 2,145 consecutive patients with essential hypertension found a 
prevalence of hyperuricemia of 35% in males and 43% in females, and this was associated 
with elevated serum creatinine levels (Lin et al., 2010). A screening among 5,722 
individuals found a 5.4% incidence of chronic kidney disease, and serum UA (sUA) 
correlated with serum creatinine levels (Chen et al., 2009). A cross-sectional study in 9,375 
participants of a health-screening program found 14.5% hyperuricemic individuals (Kuo 
et al., 2010). A screening study found a higher incidence of end-stage renal disease among 
hyperuricemic women (Iseki et al., 2004), and a post-hoc analysis in 294 patients initiating 
renal replacement therapy found that half of these were hyperuricemic with a  
twofold increase in mortality when UA levels were ≥9.0 mg/dL (≥535 µmol/l) (Suliman et 
al., 2006). 
2. Uric acid metabolism 
UA is the end-product of purine nucleotide metabolism in humans. In contrast to many 
lower vertebrates, human lack UA oxidase (uricase), an enzyme which further catalyses UA 
to allantoin, more soluble end product (Sautin & Johnson, 2008). Humans have higher 
serum UA levels when compared to other mammals due to the lack of uricase (Johnson et 
al., 2003). UA is primarily excreted via the urine. The balance between dietary intake, 
endogenous metabolism of purines and the urinary excretion rate of UA determines plasma 
UA levels (Kutzing & Firestein, 2008). 
Almost all serum UA is present in the ionized form, monosodium urate, and only about 5% of 
urate is protein bound at physiological pH. The definition of hyperuricemia is currently 
arbitrary and varies from >6 mg/dL (360µmol/l) in women and >7 mg/dL (416µmol/l) in 
men, to ≥6.5 mg/dL (387µmol/l), or to >8.3 mg/dL (494 µmol/l), regardless of gender. UA 
levels physiologically and gradually rise during the human lifetime; in female individuals, UA 
levels additionally rise after menopause (Hak et al., 2008). 
Renal handling. Kidneys eliminate two-thirds, and the gastrointestinal tract eliminates  
one-third of the UA load. Urate is filtered completely at the renal glomerulus. However,  
the normal fractional excretion of UA is only 8% to 12%. Therefore, postglomerular 
reabsorption and secretion are the ultimate factors regulating the amount of UA excretion 
(Gutman et al., 1968; Steele et al., 1973). The proximal tubule is the site of UA reabsorption 
and secretion. Almost complete reabsorption of urate occurs at the S1 segment of the 
proximal tubule. However, in the S2 segment of the proximal tubule urate is secreted at a 
range greater than reabsorption via transporters URAT1, OAT1, -2, and -3, -4, and -10, the 
multi-drug resistance proteins ABCC4 and ABCG2, and the glucose transporters GLUT 9a 
and b, and others. Finally, post-secretory resorption occurs at a more distal site of the 
proximal tubule. Approximately 10% of the filtered urate appears in the urine (Shekarriz et 
al., 2002). 
UA Chemistry. UA is a weak acid with 2 dissociation constants. Two factors contribute to 
UA solubility: UA concentration and solution pH. However, the solubility of UA in urine is 
primarily determined by urinary pH. The first pKa of UA is at a pH of 5.5, resulting in the 
loss of 1 proton from UA and the formation of anionic urate (Finlayson, 1974). The second 
pKa is 10.3, which has no physiological significance in humans. The supersaturation of urine 
with UA occurs when urinary pH is less than 5.5. In contrast, at a pH of more than 6.5 the 
majority of UA is in the form of anionic urate. The solubility of urate salts is affected by the 
relative concentrations of cations present in the urine. Increased urinary sodium 
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concentrations promote formation of the monosodium urate complex, which is more soluble 
than undissociated UA. Urine is frequently supersaturated with sodium urate but stones of 
this type are infrequent. However, supersaturation with sodium urate may contribute to 
calcium oxalate stone formation via heterogeneous nucleation.  
UA pool. UA may be derived by endogenous or exogenous routes. The endogenous 
production of UA from purine synthesis, and tissue catabolism under normal circumstances, 
is relatively constant at 300 to 400mg per day. However, the exogenous pool varies 
significantly with diet. A diet rich in animal protein contributes significantly to the purine 
pool and subsequent UA formation by a series of enzymatic reaction involving xanthine 
oxidase as the final step. 
Excretion. Renal excretion is the primary mode of UA clearance, accounting for two-thirds 
of its elimination. Intestine, skin, hair and nails account for the remaining one-third of UA 
excretion. In the intestine bacteria catabolise UA into carbon dioxide and ammonia, which 




Fig. 1. Schematic representation of the metabolism of Uric Acid 
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3. Mechanisms of uric acid-induced hypertension 
It is well established that when UA is deposited in tissues in the crystalline form, it initiates 
a proinflammatory state, as seen in gouty arthritis (Sanchez-Lozada et al., 2006). However, 
the precise pathogenetic role of soluble UA in the serum is somewhat less clear. Moreover, 
markedly elevated serum UA is clearly associated with gouty arthritis and nephrolithiasis, 
whereas the importance of subtle elevation in UA levels still remains to be established.  
For many years, UA was regarded as a metabolically inert substance. However, several lines 
of evidence have demonstrated that soluble UA is a strong antioxidant (Ames et al., 1981). 
Despite these well-recognized antioxidant effects, UA also behaves as a pro-oxidant and 
proinflammatory factor. A few points should be emphasized to better understand this 
apparent paradox. First, UA acts differently inside the cells or in the extracellular milieu, 
where it is present in soluble form. While being a potent antioxidant in extracellular fluid, 
UA exerts pro-oxidative effects once inside the cell (Sautin et al., 2007; Corry et al., 2008; 
Convento et al., 2011). 
Second, one isoform of xanthine oxidoreductase – xanthine dehydrogenase – undergoes 
extensive phenotypic conversion to xanthine oxidase under local ischemic conditions. 
Unlike xanthine dehydrogenase, xanthine oxidase uses molecular oxygen instead  
of Nicotinamide Adenine Dinucleotide (NAD) as an electron acceptor (Glantzounis et  
al., 2005).  
In addition to interference with free radical production, UA has some direct effects on 
endothelial and smooth muscle cells of the vascular wall, which ultimately lead to 
endothelial dysfunction (Mazzali et al., 2002). In endothelial cells, UA blocks nitric oxide 
(NO) release, inhibits endothelial proliferation and stimulates C-reactive protein production 
(Khosla et al., 2005). Several experimental studies also showed that UA can activate smooth 
muscle cells via activation of  specific MAP kinases, nuclear transcription factors, 
stimulation of ciclooxigenase-2 (Cox-2), and various inflammatory mediators such as the 
tissue renin-angiotensin system (Corry et al., 2008; Watanabe et al., 2002; Kang et al., 2002). 
Recent evidence also suggests that hyperuricemia increased cellular proliferation, 
angiotensin II (AII) and endothelin-1 (ET-1) in human mesangial cells (Albertoni et al., 2010), 
which could contribute to reduce GFR. 
In a landmark study by Mazzali et al., 2001 pharmacologically induced mild-to-moderate 
hyperuricemia via oxonic acid administration in rats resulted in the development of 
hypertension. Conversely, when UA elevation was treated with allopurinol or with a 
uricosuric agent, development of hypertension could be prevented. Other experimental 
studies show that at a concentration of 10 mg/dL UA significantly decreases the production 
of ET-1 in mesangial cells after 24h of treatment.  This effect was blocked by Losartan (LOS), 
an AII receptor type 1 antagonist (Albertoni et al, 2010). 
It is also possible that genetic polymorphisms of transporters or enzymes involved in UA 
metabolism affect blood pressure, especially in younger subjects. For example, hypertension 
has been associated with polymorphisms of xanthine oxidoreductase (Chaves et al., 2007). 
4. Uric acid and acute renal failure 
Uric acid, as the end-product of purine metabolism in humans, presents a clinical impact 
since its has a relative insolubility, particularly in the acidic environment of the distal 
nephron. As a result, states of enhanced purine catabolism increases the urate load on the 
kidney, leading to intrarenal precipitation. Major causes of increases on purine metabolism 
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are malignancies with rapid cell turnover, such as leukemia and lymphomas, and the added 
acceleration of cell lyses that occurs with chemotherapy and radiation. Serum urate levels 
rise rapidly, and acute renal failure occurs as a consequence of tubular deposition and 
obstruction  of urate and uric acid. The keys to the diagnosis of acute uric acid nephropathy 
are the appropriate clinical settings as cell lyses increases, oliguria, marked hyperuricemia, 
and hyperuricosuria. A urinary uric acid-to-creatinine ratio greater than 1 helps to 
distinguish acute uric acid nephropathy from other catabolic forms of acute renal failure in 
which serum urate is elevated. Preventive treatment involves pharmacologic xanthine 
oxidase inhibition with allopurinol and alkaline diuresis. Occasionally, acute renal failure 
occurs despite allopurinol due to tubular precipitation of the metabolites precursors, such as 
xanthine, which accumulate with xanthine oxidase inhibition. Dialysis therapy may be 
required both to correct azotemia and to reduce the body burden of urate. Hemodialysis is 
preferred since it can achieve greater clearance than other dialysis modes. (Conger, 1990). 
5. Uric acid and kidney disease 
Association of UA with chronic kidney disease dates back to 1890s. Any functional declive 
which reduces glomerular filtration rates (GFR) and tubular reabsorption secondarily leads 
to UA elevation, but also the decrease in glomerular filtration rate can increase serum UA 
(Feig, 2009). To determine which comes first was the principal endeavor of UA researchers 
in the last two decades.  
Experimental studies performed by Mazzali et al., 2002, demonstrated that hyperuricemic 
rats developed hypertension, afferent arteriolopathy, glomerular hypertrophy, and 
increased glomerular pressure, tubulointerstitial damage and macrophage infiltration 
(Mazzali et al., 2002; Sanchez-Lozada et al., 2005; Nakagawa et al., 2003). 
Several works analyzed the effects of UA in kidney cells and hyperuricemic animal models. 
Firstly, hyperuricemia induces endothelial dysfunction and inflammation (Yu et al., 2010, 
Khosla et al., 2005). UA has the ability to increase monocyte chemoattractant protein (MCP-
1) in cultured vascular smooth muscle cells (Kanellis et al., 2003) and human proximal 
tubular epithelial cells (Cirillo et al., 2006). UA can induce the contraction (Albertoni, et al., 
2010) and reactive oxygen species produced in mesangial cells (Convento et al., 2011). 
6. Uric acid, metabolic syndrome and diabetes 
The relationship between hyperuricemia, hypertension, and the metabolic syndrome has long 
been debated. Are the conditions different manifestations of a common underlying metabolic 
disorder? Is hyperuricemia in part responsible for hypertension? Recent evidences from 
animal studies and epidemiology suggest that hyperuricemia has a primary role in both 
hypertension and the metabolic syndrome. Rats that were made hyperuricemic rapidly 
developed hypertension through activation of the renin-angiotensin system, induction of 
endothelial dysfunction, and vascular smooth muscle proliferation. Lowering UA in these 
animals prevented this effect (Johnson et al., 2005). In a longitudinal study in children, there 
was a strong correlation between hyperuricemia and the subsequent development of 
hypertension (Feig et al., 2006). Recent epidemiological data suggest also that hyperuricemia is 
an independent risk factor for developing hypertension. In a group of subjects who did not 
have the metabolic syndrome, normotensive men with baseline hyperuricemia had 80% more 
risk of develop hypertension compared with those who did not have hyperuricemia (Krishnan 
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et al., 2007). Finally, the degree of hyperuricemia is strongly correlated with the prevalence of 
the metabolic syndrome (Yoo et al., 2005; Choi et al., 2007; Facchini et al., 1992). 
Metabolic syndrome has many components which may independently mediate or lead to 
kidney damage, including increased inflammation (Calabro & Yeh, 2008), insulin resistance 
and endothelial dysfunction (Kim et al., 2006). Additionally, diets high in fructose constitute 
one of the major predisposing factors for the metabolic syndrome epidemia (Cirillo et al., 
2006). Fructose is unique among sugars by its ability to rapidly deplete ATP, with resultant 
purine nucleotide degradation and eventual UA generation. 
Experimental studies in rodents have suggested that UA may contribute to the development 
of the metabolic syndrome, hypertension, and kidney disease (Feig et al., 2008) and recently 
clinical studies focusing on UA and the development and progression of diabetic kidney 
disease have been published (Hovind et al., 2011). In the early report of the Modification of 
Diet in Renal Disease Study (Hunsicker et al., 1997), UA was not found to be an independent 
predictor for renal disease. Others large epidemiologic studies have revealed conflicting 
results in this respect. While the majority (Iseki et al., 2001; Domrongkitchaiporn et al., 2005; 
See et al., 2010; Chang et al., 2010; Obermayr et al., 2008) of these studies suggest an 
independent predictive role for UA in renal disease, others (Tomita et al., 2000; Sturm et al., 
2008; Madero et al., 2009) argue against it.  
Historically, the elevated level of UA observed in the metabolic syndrome has been attributed 
to hyperinsulinemia, since insulin reduces renal excretion of UA (Quinõnes et al., 1995).  
Hyperuricemia, however, often precedes the development of hyperinsulinemia (Nakagawa 
et al., 2005; Carnethon et al., 2003), obesity (Masuo et al., 2003), and diabetes (Nakanishi et 
al., 2003; Dehghan et al., 2008; Chien et al., 2008). Hyperuricemia may also be present in the 
metabolic syndrome in people who are not overweight or obese.  
The strongest evidence of a role for UA in the development of the metabolic syndrome has 
been from studies models showing that decreasing UA levels can prevent or reverse features 
of the metabolic syndrome (Nakagawa et al., 2006; Sanchez-Lozada et al., 2008; Reungjui et 
al., 2007). Two mechanisms have been suggested to explain how hyperuricemia might 
induce the metabolic syndrome. The first mechanisms is related to the fact that glucose 
uptake in skeletal muscle depend in part on increases in blood flow mediated by the insulin-
stimulated release of NO from endothelial cells. Features of the metabolic syndrome 
develop in mice lacking endothelial nitric oxide synthase (iNOs) (Cook et al., 2003). The 
observations that hyperuricemia can induce endothelial dysfunction in rats (Khosla et al., 
2005) and that treatment with allopurinol can improve endothelial function in patients with 
hyperuricemia (Mercuro et al., 2004) would support this mechanism. The second 
mechanism concerns the inflammatory and oxidative changes UA induces in adipocytes 
(Sautin et al., 2007), a process that is key in causing the metabolic syndrome in obese mice 
(Furukawa et al., 2004).  
The prevalence of diabetes, and for that matter the associated complications, has increased 
dramatically. Presently, diabetes is the leading cause of end-stage renal disease in the 
western world (United States Renal Data System, 2008). Although the progression of renal 
disease can be halted partially, diabetic nephropathy is still regarded as an irreversible and 
progressive disease (Parving et al., 2008). 
Therefore, it has become increasingly essential to determine the pathophysiological 
mechanisms underlying the development and progression of diabetic nephropathy. 
Evidence is available of a complicated interaction between different contributors to the 
disease process. It is possible that genetic susceptibility, metabolic abnormalities, 
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hemodynamic changes, upregulated growth factors, and cytokines may all play a part in the 
development of diabetic glomerulopathy; however, the complex pathogenesis of 
development of diabetic nephropathy has not been fully clarified (Hovind et al., 2011). 
Recently clinical studies focusing on UA, albuminuria and diabetic kidney disease have 
been published (Bonakdaran et al., 2011; Kim et al., 2010; Kuo et al., 2010). The new evidence 
suggests that UA could be a risk factor for the development of diabetic nephropathy; 
however, the significance of serum UA as pathogenic factor in the development of diabetic 
nephropathy is not yet fully clarified (Hovind et al., 2011). 
7. Uric acid stones 
A high concentration of urate and low pH are the determinants of UA stone formation. 
The prevalence of UA stones in the United States is estimated to be 5% to 10% (Gutman et 
al., 1968). Interestingly, these data originate from studies performed more than 30 years 
ago. Therefore, the current incidence of UA stones in the United States may be different. 
In a more recent study from Veterans Administration hospital stone analyses revealed 
that 12% of stones contained some UA component and 9.7% comprised pure UA (Mandel 
et al., 1989). Incidence also may vary with age. The incidence of UA stones was 11% in a 
geriatric population (Gentle et al., 1997). The frequency of UA stones also varies in 
different geographical locations within the United States. In southern states the incidence 
has been reported at 4% compared with 17% in Chicago (Riese et al., 1992). Other 
industrialized countries have wide variations in UA stone rates, with Germany reporting 
17% to 25%, Sweden 4% and Israel up to 40% (Hesse et al., 1975; Scholz et al.,  
1979; Grenabo et al., 1985; Atsmon et al., 1963). Urate stones have frequently been 
reported in Iran and Pakistan. However, the majority of these stones are ammonium acid 
urate (Minon et al., 1983). These apparent geographical variations indicate that genetic, 
dietary and environmental factors may have an important role in the formation of  
UA stones. 
Composition and different types of UA stones. UA stones can be classified based on 
crystalline composition as anhydrous uric acid, uric acid dehydrate, sodium acid urate 
monohydrate or ammonium acid urate (Halabe et al., 1994). The anhydrous form is 
thermodynamically the most stable crystal. The dehydrate form is unstable and undergoes 
dehydration to the anhydrous form. Uric acid dehydrate has been identified in 20% of UA 
calculi and may represent the entire component. Ammonium acid urate precipitation 
requires high urate and ammonium concentrations and occurs at a higher pH. Recently, a 
classification of UA stones based on their crystalline growth pattern has been suggested 
(Grases et al., 2000). 
Mechanism of stone formation. UA stone formation requires supersaturation of urinary 
UA. Three factors contribute to the formation of these calculi: acidic urine, hyperuricemia 
and decreased urinary volume. One or more of these conditions may coexist in a specific 
patient and contribute to stone disease severity (Shekarriz et al., 2002). 
Hyperuricosuria. Hyperuricosuria is defined as a mean 24-hour urinary UA excretion of 
more than 600 mg/24 hr in 2 of 3 collected samples (Pak et al., 1980). Hyperuricosuria may 
be associated with hyperuricemia, such as in primary gout, or may manifest as an isolated 
abnormality due to various factors such as diet or medications. The degree of hyperuricemia 
correlates with the incidence of UA stone formation. In patients with gout the incidence of 
UA stones was 23% in those with urinary UA levels less than 600 mg/24hr compared with 
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50% in those with UA levels greater than 1,000 mg/24 hr (Yu et al., 1967). In other study 
11% of patients with UA excretion less than 300 mg/24 hr had UA stones (Hall et al., 1967; 
Katz et al., 1970). In patients with gout the rate of stone formation is higher when uricosuric 
drugs are administered.  
Urinary pH. All conditions contributing to acidic urine promote uric acid stone formation. 
Urinary pH is abnormally low in a significant number of patients with gout and in 
idiopathic UA stone formers (Gutman et al., 1968; Yu et al., 1967; Zechner et al., 1982; Ito et 
al., 1995). Urinary alkalization is the cornerstone of medical management of UA stones. The 
concept of UA stone dissolution is not new. Shekarriz et al., 2002 observed impressive 
dissolution of large burden UA renal stones with oral alkalization. UA stone dissolution by 
oral alkalization is generally effective, with a reported success rate of 80% (Shekarriz et al., 
2002). Continued alkalization will help prevent future stones, but in the treatment of gout, 
alkalinization  of urine (over pH 6.5) to maintain the solubility may precipitate calcium 
phosphate crystals (Meyer et al., 1990). 
8. Gout 
Gout is a disease of ancient origin and its association with UA stones has long been 
recognized. In 1683 London physician Thomas Sydenham, who suffered from renal stones, 
described the clinical features of gout. Michelangelo’s special interest in anatomy and 
kidney function has been ascribed to his own urinary stone disease (Eknoyan et al., 2000).  
Studies of the composition of urinary calculi were limited before the advent of modern 
chemistry. Gout is an inflammatory process initiated by tissue deposition of monosodium 
urate (MSU) crystals. A typical attack is an acute monoarthritis accompanied by classical 
signs of inflammation. However, inflammation can occur in any tissue in which MSU is 
deposited, as typified by tophaceous gout and by urate nephropathy due to renal medullary 
deposition of MSU crystals (So, 2008).  
Multiple risk factors may interact and lead to development of gout: 
Genetics – Monogenic disorders that result in overproduction of UA via enzyme defects in 
purine metabolism are extremely rare. Nevertheless, common primary gout in men often 
shows strong familiar predisposition, although the genetic basis remains unknown. Twin 
studies have show high heritability for both UA renal clearance (60%) and UA: creatinine 
ratio (87%) and several susceptibility loci for this have been reported (Roddy et al., 2007). 
Gender and age – Men have higher urate levels than women and an increased prevalence of 
gout at all ages, though less pronounced in older age. Estrogens have a uricosuric effect, 
making gout very rare in younger women. However, after the menopause, urate levels rise 
and gout becomes increasingly prevalent. Ageing is an important risk factor in both  
men and women, possibly due to multiple factors including: an increase in sUA levels 
(mainly due to reduced renal function); increased use of diuretics and others drugs that 
raise sUA; age-related changes in connective tissues, which may encourage crystal 
formation (Roddy et al., 2007). 
Diet – Historically, gout has long been linked with a rich lifestyle involving excesses of meat 
and alcohol, but it is only recently that population studies have been undertaken to 
determine the risk associated with individual dietary components. Data from the large 
Health Professionals Follow-up Study (HPFS) have show that the relative risk of gout is 
higher in people who eat a high red meat diet: the relative risk of a first attack of gout 
associated with an additional daily portion of meat was 1.21 (95% CI 1.04, 1.41). Higher 
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consumption of seafood was associated with a lesser, but still significant, increase in risk. 
Diets high in purine-rich vegetables did not increase the risk, while diets high in low-fat 
dairy products were associated with reduced risk (relative risk with additional daily 0.79; 
95% CI 0.71, 0.87) (Choi et al., 2004). 
Alcohol – Some alcoholic drinks are rich in purines, notably beer which contains guanosine. 
Alcohol is though to increase the risk of gout because the metabolism of ethanol to acetyl 
CoA leads to adenine nucleotide degradation, resulting in increased formation of adenosine 
monophosphate, a precursor of UA. Alcohol also raises the lactic acid level in blood, which 
inhibits UA excretion. In the HPFS, overall the higher the daily alcohol intake, the higher the 
risk of gout (Choi et al., 2004). However, differences in risk were observed with different 
alcoholic drinks. Beer had the greatest effect, probably because of its high purine content, 
then alcohol, whereas wine had no increased risk (Choi et al., 2004). 
Drugs – Many drugs which either increase sUA levels (e.g. diuretics and pyrazinamide) or 
reduces sUA levels (e.g.uricosurics such as benzbromarone, sulphinpyrazone and vitamin 
C) effect these changes via interaction with urate transporters such as URAT1 (Anzai et al., 
2005) and GLUT9 (Caulfield et al., 2008). 
RENAL DISEASE AND GOUT – Gout frequently associates with kidney disease, each 
being a risk factor for the other. Primary kidney disease can lead to hyperuricemia and it has 
been suggested that the increasing prevalence of end-stage renal disease may be one cause 
of recent increases in gout (Roddy et al., 2007). Kidney damage secondary to gout is 
associated with urate crystals and microtophi in the interstitium and/or UA crystals within 
tubules. Evidence from animal studies suggests that hyperuricemia may accelerate chronic 
kidney disease, and several studies have demonstrated a significant and independent 
association between sUA levels and the progression of chronic kidney disease (Kang et al., 
2002; Kang et al., 2005). A history of gout is an independent risk factor for urolithiasis in 
men (Kramer et al., 2003). The increased risk is not just for UA stones, but also for more 
common calcium phosphate stones. High urinary levels of UA increase the risk of stone 
formation and in gout patients, the higher the excretion of UA, the greater the risk of stone 
formation (Yu et al., 1967). However, the most important risk factor for UA stone formation 
is persistently acidic urine, favoring the precipitation of urate (Shekarriz et al., 2002). In 
patients with UA stones, a high urinary UA: creatinine ratio indicates overproduction of 
UA, which should prompt a search for an abnormality of purine metabolism. 
9. Advances in therapy of hyperuricemia and gout 
The treatment of hyperuricemia and gout remains a challenge even though we appear to 
have a number of effective drugs. Many clinicians recognize that our existing treatment 
choices are often limited in the routine clinical setting. Allopurinol, the most commonly 
used drug to treat hyperuricemia, can provoke severe allergic-type reactions and needs to be 
used with caution in renal failure. Fortunately, the incidence of these rare reactions is low, 
but skin rashes are frequently reported (Hung et al., 2005). Benzbromarone, a very effective 
uricosuric drug, was recently withdrawn from general distribution because of a number of 
cases of hepatic failure associated with its use. Other hypouricemic drugs are therefore 
needed. Recently, a new xanthine-oxidase inhibitor, febuxostat, underwent clinical trials and 
was show to be as effective as allopurinol in reducing hyperuricemia (Becker et al., 2005). 
Febuxostat, unlike allopurinol, is not a purine analog and does not cross-react with 
allopurinol. In clinical trials, when administered at a daily dose of either 80 or 120 mg, it was 
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more effective than a 300 mg daily dose of allopurinol in achieving the target value of 
uricemia (less than 6 mg/dL or less than 360 µmol/L), a target that has been recommended 
in treatment guidelines for gout and hyperuricemia (Zhang et al., 2006). 
10. Conclusion 
It is becoming clear that the role of UA is no longer confined solely to gout and 
nephrolithiasis. Increasing evidence now points to a significant relation of UA to 
hypertension and renal disease. Moreover, recent studies have started to unveil the causal 
nature of this relationship in both hypertension and renal disease. Despite considerable 
progress, given the numerous confounders, more compelling evidence is needed before 
ultimately labelling UA as a causative factor in hypertension and renal disease. Persistently 
acidic urine resulting in supersaturation of UA is the only metabolic abnormality found in 
many patients with UA stones. Although the mechanism responsible for acidic urine in 
many patients remains unclear, urinary alkalization is the cornerstone of medical 
management and should be the primary mode of treatment in the absence of absolute 
indications for surgical intervention. Furthermore, prophylaxis with urinary alkalization 
using oral alkali prevents stone recurrence and associated morbidity. Hyperuricemia is the 
central risk factor for gout and is a key component of the metabolic syndrome, is also an 
independent risk factor for cardiovascular disease, although at present there is no evidence 
to support urate-lowering therapy for asymptomatic hyperuricemia. More studies in this 
exciting and provocative area of research are being conducted and published (Kanbay et al., 
2007; 2010; Turgut et al., 2009). 
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